Response to the letter “Ambulatory oxygen: Is the 6 minute walk test the best option?”  by Vieira, T. et al.
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esponse to the letter ‘‘Ambulatory
xygen: Is the 6 minute walk test
he best option?’’
esposta à carta ‘‘Oxigenoterapia de
eambulac¸ão: será o teste de 6 minutos de
archa a melhor opc¸ão?’’
e would like to thank the authors for their comment on our
rticle1 about the study on the prescription of ambulatory
xygen (AO) and for raising very pertinent and important
ssues.
Our ﬁndings of relatively low adherence to prescribed
O are consistent with other studies, for example, a recent
talian survey2 which conﬁrmed that only 41% of the patients
eported used liquid oxygen when outside the house.
In our study we clearly deﬁned the criteria for use of AO;
hese consisted of exercise hypoxemia which is documented
y a standardized 6-min walk test (6MWT) on air, evidence
f signiﬁcant desaturation (to 88% or less), the patient being
esponsive to oxygen, and signiﬁcant daily activity. Accord-
ng to our data, positive response during the 6MWT did not
elp to predict greater use of the portable oxygen systems
POS). This led us to the conclusion, highlighted in the arti-
le, that non-adherence to AO may be closely related to the
ocial stigma or the physical characteristics (like weight) of
he POS.
The authors correctly discuss the role of the 6MWT in
rescribing AO. In fact, although the ATS statement on the
MWT3 is not very clear in relation to prescribing AO, some
uthors have suggested the need for up to ﬁve 6MWT. To min-
mize the learning effect, the ﬁrst two are training sessions,
ne of which may be performed with the patient carry-
ng the weight of the oxygen source,4 and then the oxygen
itration should be performed after three 6MWT to evaluate
he effect of breathing air and two different oxygen doses.5
owever, there is no standard titration method. According to
he COPD ATS Guidelines it is recommended that the rest-
ng ﬂow rate be increased by 1l/min during exercise.6 We
pted to perform the walk test with the highest ﬂow possible
6 L/min) because in some studies doubling the resting dose
as not sufﬁcient to prevent hypoxemia 4 and we wanted
o make sure of providing adequate oxygenation during all
ctivities. Moreover, we do not believe that in the real world
he repetition of so many 6MWT is actually feasible and, in
act, 26% of respirologists around the world do not perform
should be followed by a review after two months when the
true value of AO can be judged by interview, diary card and
oxygen usage’’. In addition home follow-up within 4 weeks
is strongly recommended. Without this monitoring patients
might use systems or settings that do not maintain adequate
oxygenation and as a consequence their physical activity is
restricted and the health beneﬁts lost. In our centre this
strict protocol is not followed and so long-term compliance
with AO can be affected.
We believe, therefore, that the acute assessment should
be only one component of an AO evaluation. Objective
compliance of oxygen use is urgently needed and newly
designed Oxygen Therapy Monitoring Devices can improve
the management of these patients.9
As we stated (because acute improvements in 6MWT
parameters do not help predict outdoor activities) we need
better tests to identify those who really respond to AO.
As has been suggested by Vonbank et al.10 hemodynamic
response to oxygen can be a better predictor. Others have
implied that the more hyperinﬂated COPD patients are the
ones that can beneﬁt most11 or we may even have to be
more stringent in the criteria for AO prescription as sug-
gested by Leach et al.5 and only consider those who show
50% improvement in exercise ability!
One thing is certain, although we have to increase the
consensus around AO prescription, repeated educational
sessions are deﬁnitely needed to improve compliance to
long-term oxygen therapy.
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